Dublin, Jan. 03, 2020 (GLOBE NEWSWIRE) -- The "The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.

The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across:

• [A] type of therapy (prescription drugs, prebiotics, and probiotics)
• [B] type of molecule (small molecules and biologics)
• [C] target indication (acne vulgaris, atopic dermatitis, CDI, Crohn's disease, diabetes, irritable bowel syndrome, lactose intolerance, nonalcoholic steatohepatitis (NASH), ulcerative colitis, and 5+ categories)
• [D] therapeutic area (autoimmune disorders, dental disorders, digestive and gastrointestinal disorders, dermatological disorders, infectious diseases, metabolic disorders, oncology, and others)
• [E] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies)
• [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world)
• [G] leading drug developers
• [H] leading therapeutic products

In addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across:

• [A] target indication (Crohn's disease, colorectal cancer, diabetes, irritable bowel syndrome, lung cancer, NASH, obesity, and ulcerative colitis)
• [B] therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncology)
• [C] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies)
• [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world)
  

In addition to other elements, the study includes:

• A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.
• Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.
• A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.
• A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.
• A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
• An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
• An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.
• An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.
• An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.
• An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.
• An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.
• An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.

In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Key Topics Covered

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Microbiota and Microbiome
3.3. Overview of Gut Flora
3.4. The Microbiome and Disease
3.5. Impact of Microbiota on Drug Pharmacokinetics
3.6. Impact of Microbiota on Therapeutic Outcomes
3.7. Microbiome Therapeutics
3.8. The Human Microbiome Project (HMP)
3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
3.10. Key Challenges in the Development of Microbiome Therapeutics
3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbiome Therapeutics: Clinical Pipeline
4.3. Microbiome Therapeutics: Early-Stage Pipeline
4.4. Microbiome Therapeutics: List of Drug Developers
4.5. Microbiome Therapeutics: List of Discontinued Drugs
4.6. Emerging Role of Microbiome in Gut-Brain Axis
4.7. Microbiome Therapeutics: List of Technology Platforms

5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. 4D Pharma
5.3. Armata Pharmaceuticals
5.4. Evelo Biosciences
5.5. Rebiotix (Acquired by Ferring Pharmaceuticals)
5.6. Seres Therapeutics
5.7. Vedanta Biosciences

6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Overview of Microbiome Diagnostic Tests
6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products
6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers
6.5. Profiles of Prominent Diagnostic Developers
6.6. Overview of Microbiome Screening / Profiling Tests

7. FECAL MICROBIOTA THERAPY (FMT)
7.1. Chapter Overview
7.2. Introduction to FMT
7.3. Historical Overview
7.4. FMT: Procedure and Clinical Relevance
7.5. Regulatory Guidelines Related to FMT
7.6. Insurance Coverage for FMT
7.7. FMT: Competitive Landscape
7.8. Clinical Trial Analysis (Non-Industry Sponsored)
7.9. Stool Banks

8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
8.1. Chapter Overview
8.2. AC Matrix: An Overview
8.3. AC Matrix: Analytical Methodology
8.4. AC Matrix: Plotting the Information
8.5. AC Matrix: Analyzing the Data
8.6. Concluding Remarks

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Initiatives of Big Pharmaceutical Players
9.4. Benchmark Analysis of Big Pharmaceutical Players

10. START-UP HEALTH INDEXING
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Benchmark Analysis of Start-ups

11. KEY THERAPEUTIC AREAS
11.1. Chapter Overview
11.2. Metabolic Disorders
11.3. Digestive and Gastrointestinal Disorders
11.4. Oncological Indications
11.5. Dermatological Disorders
11.6. Infectious Diseases

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
12.4. Concluding Remarks

13. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS
13.1. Chapter Overview
13.2. Manufacturing Microbiome Therapeutics
13.3. Microbiome Therapeutics-related R&D
13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner

14. BIG DATA AND MICROBIOME THERAPEUTICS
14.1. Chapter Overview
14.2. Introduction to Big Data
14.3. Internet of Things
14.4. Growing Interest in Big Data: Google Trends Analysis
14.5. Key Application Areas
14.6. Big Data in Microbiome Research
14.7. Big Data Services for Microbiome Research: List of Companies
14.8. Big Data Services for Microbiome Research: Profiles of Key Players

15. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology
15.4. Overall Microbiome Therapeutics Market, 2019-2030
15.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030

16. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope and Limitations
16.3 Forecast Methodology
16.4. Overall Microbiome Diagnostics Market, 2019-2030
16.5. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030
16.6. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030
16.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-2030
16.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030

17. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Limitations
17.3. Forecast Methodology
17.4. Overall FMT Market, 2019-2030
17.5. Overall Microbiome Market by Product Offerings, 2019-2030

18. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES
18.1. Chapter Overview
18.2. List of Microbiome Products in Other Industries
18.3. Applications of Microbiome Based Products in Agriculture Industry
18.4. Future Prospects

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS
20.1 Chapter Overview
20.2. Rebiotix
20.3. S-Biomedic
20.4. Whole Biome
20.5. Siolta Therapeutics
20.6. OpenBiome
20.7 Assembly Biosciences
20.8. List Biological Laboratories
20.9. Metabiomics
20.10. MicroBiome Therapeutics
20.11. Universal Stabilization Technologies
20.12. BiomX
20.13. Da Volterra
20.14. Chung Mei Pharmaceutical
20.15. Pacific Northwest National Laboratories

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

• 16S Technologies
• 4D Pharma
• 5QBD-Biotech
• Aalborg University Hospital
• Aarhus University
• AB-Biotics
• Abbott Laboratories
• AbbVie
• Abraxis BioScience
• Academic Medical Centre (Amsterdam UMC)
• ActoBio Therapeutics
• Adapsyn Bioscience
• Adare Pharmaceuticals
• AdvancingBio
• AEProbio
• Aetna
• AgBiome
• Ajuvis Labsd
• Alaven Pharmaceutical
• Aleris-Hamlet Hospital
• Alimentary Health (Part of PrecisionBiotics Group)
• Alimentary Pharmabiotic Centre Microbiome Institute, University College Cork (UCC)
• Allergan
• Allergy Therapeutics
• Altis Biosystems
• Amabiotics
• Amazon
• American College of Gastroenterology
• Ample
• AmpliPhi Biosciences
• Amrita Therapeutics
• Anavex Life Sciences
• AnimalBiome
• ANIZOME
• AOBiome Therapeutics
• Ardigen
• Arena Pharmaceuticals
• Arizona State University
• Armata Pharmaceuticals
• Artizan Biosciences
• ARTPred
• Ascus Biosciences
• Asia Microbiota Bank
• AsiaBiome (formely known as Civet Biosciences)
• Assaf Harofeh Medical Center
• Assembly Biosciences
• APHM (Public Assistance - Marseille Hospitals)
• APHP (Public Assistance - Paris Hospitals)
• Astarte Medical
• Astel Medica
• AstraZeneca
• Atlas Biomed
• Autonomous University of Nuevo Len
• Aventis Pharma
• AvidBiotics
• Axcan Pharma
• Axial Biotherapeutics
• Azitra
• Bactana
• Bayer
• Baylor College of Medicine
• Becton Dickinson
• Beiersdorf
• Beth Israel Deaconess Medical Center
• Bio Farma
• Biocartis
• Biocodex
• BioControl (Acquired by Merck)
• BioGaia
• Biogen
• Biohit Healthcare
• BIOHM Health
• Bio-K Plus International
• Biom Pharmaceuticals
• BioMathematica
• BiomCare
• Bio-Me
• Biome Makers
• Biome360
• BiomeBliss
• Biomecite Diagnostics
• BiomeSense
• Biomica (subsidiary of Evogene)
• Biomillenia
• BiomX
• BioRankings
• Biorasi
• biose
• Biotagenics
• Blis Probiotics
• Blue Biology
• Blue Turtle Bio
• Boehringer Ingelheim
• BoobyBiome
• Boston Children's Hospital
• Boston Medical Center
• Brigham and Women's Hospital
• Bristol-Myers Squibb
• BugSpeak
• Caelus Health
• California Institute of Technology (Caltech)
• Campus Bio-Medico University
• Canadian Association of Gastroenterology
• Canadian Institutes of Health Research
• Capsugel
• Captozyme
• Carbiotix
• CARB-X
• Careggi University Hospital
• Case Comprehensive Cancer Center
• Catholic University of the Sacred Heart
• Cedars-Sinai Medical Center
• Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology
• Center of Food and Fermentation Technologies
• Centers for Disease Control and Prevention
• CHAIN Biotechnology
• Charles River Laboratories
• Children's Hospital Los Angeles
• Children's Hospital of Philadelphia
• Children's Mercy Hospital Kansas City
• Chr. Hansen
• Chugai Pharmaceutical
• Chung Mei Pharmaceutical
• ChunLab
• Cigna
• CIPAC Healthcare
• Clasado BioSciences
• ClearB Therapeutics
• Clinical Investigation Center for Innovative Technology Network
• Clinical Microbiomics
• ClostraBio
• Cobra Biologics
• Commense (a subsidiary of PureTech Health)
• Concentric Ag
• Cook MyoSite
• CoreBiome
• Cornell University
• CosmosID
• Covaris
• CRB-HUEP
• Crohn's & Colitis Foundation
• CRS Bio
• Cykinso
• Dairy & Food Culture Technologies
• Dakota BioTech
• Danisco
• Da Volterra
• Dayanand Medical College & Hospital
• DayTwo
• DermBiont
• Diagnostic Solutions Laboratory
• Diversigen
• DNA Genotek
• Duke University
• DuPont
• Eagle Genomics
• Eat Troo
• Eatrics
• Edico Genome (Acquired by Illumina)
• EirGenix
• Eli Lilly
• ELiE Health Solutions
• Embion Technologies
• EmblemHealth
• Emory University
• Emulate
• Englewood Health
• Enterin
• EnteroBiotix
• Enterome Bioscience
• EpiBiome (Acquired by Locus Biosciences)
• Esse Skincare
• European Commission
• European Society of Clinical Microbiology and Infectious Diseases
• Evelo Biosciences
• Evolve BioSystems
• Evotec
• EXDEN
• Exeliom Biosciences (formerly known as Nextbiotix)
• EzBioCloud
• Fecal Microbiota Transplantation Workgroup
• Federal Research and Clinical Center of Physical-Chemical Medicine
• FermBiotics
• Ferring Pharmaceuticals
• Finch Therapeutics
• First Affiliated Hospital of Chengdu Medical College
• Flora Medicine
• Floragraph
• First Affiliated Hospital of Nanchang University
• Fortify
• Foundation of Hope
• Fourth Military Medical University
• Frontier Science & Technology Research Foundation
• FUJIFILM Diosynth Biotechnologies
• Fuzhou General Hospital
• G.D Searle
• Galderma
• Galline
• GALT
• Genetic Analysis
• Institute of Molecular Genetics Academy of Sciences Czech Republic
• GENEWIZ
• Genome and Company
• Genova Diagnostics
• Genten Therapeutics
• German Federal Ministry of Education and Research
• Ghent University
• GI Innovation
• Ginkgo Bioworks
• Global Cosmetics
• GNUbiotics Sciences
• GoodBelly
• GoodGut
• Groken Bioscience
• GlaxoSmithKline
• GT Biologics
• Guangzhou First People's Hospital
• Glhane Institute of Health Sciences
• Gusto Global
• Hadassah Medical Center
• Hamilton Health Sciences
• Harvest Capital Strategies
• Haukeland University Hospital
• Health Net
• HealthPartners
• University of Helsinki
• Hoechst Marion Roussel
• Holobiome
• Hospital District of Helsinki and Uusimaa
• Hospital for Sick Children
• Hospital Ramn y Cajal
• Hudson Institute of Medical Research
• Human Longevity
• Hunter Holmes McGuire Veterans Administration Medical Center
• Hvidovre Hospital
• Hy Laboratories
• Hyggut
• IBM
• Icahn School of Medicine at Mount Sinai
• iCarbonX
• Igen Biolab Group
• ImClone Systems
• ImmuneBiotech
• Immunex
• Immuron
• Indiana University
• Indigo Therapeutics
• Inserm
• Institut Allergosan
• Institut national de la recherche agronomique
• Institute for Clinical and Experimental Medicine
• The Institute of Animal Physiology
• Institute of Liver and Biliary Sciences
• Intralytix
• Intrexon
• Intuition Biosciences
• Invivo Healthcare
• Ipsat Therapies
• Ironwood Pharmaceuticals
• IS-Diagnostics
• Island Health
• Isohelix
• ISOThrive
• Ixcela
• Ixion Biotechnology
• J. Craig Venter Institute
• Janssen Biotech
• Jena University Hospital
• Jinling Hospital
• John Theurer Cancer Center
• Johnson & Johnson
• Joint Authority for Pijt-Hme Social and Health Care
• Juno Bio
• Kaleido Biosciences
• Kallyope
• Karolinska Institutet
• Kelsey Research Foundation
• Keystone Bio
• King's College London
• Kingston Health Sciences Centre
• Kintai Therapeutics
• KNOMICS MICROBIOTA
• Kobiolabs
• La Trobe University
• Laboratorio Cobas
• Lactobio
• Lallemand Health Solutions
• Lavie Bio
• Lawrence Berkeley National Laboratory
• Lawson Health Research Institute
• Leadiant Biosciences
• Leiden University
• Lesaffre Human Care
• Levanger Hospital
• List Biological Laboratories
• LNC Therapeutics
• Locus Biosciences
• London Health Sciences Centre
• Lonza
• Lovisenberg Diakonale Hospital
• LUCA Biologics
• Luina Bio
• Luxia Scientific
• M.D. Anderson Cancer Center
• MaaT Pharma
• Madison University
• Maiden Therapeutics
• Mankind Pharma
• Manufacturer Vilhelm Pedersen Foundation
• Marqus de Valdecilla University Hospital
• Masonic Cancer Center
• Massachusetts General Hospital
• Massachusetts Institute of Technology
• MatriSys Bioscience
• Mayo Clinic
• McMaster University
• MD Anderson Cancer Center
• Medeva Pharmaceuticals
• Medical College of Wisconsin
• Medical University of Graz
• Medlab
• Memorial Medical Center Foundation
• Memorial Sloan Kettering Cancer Center
• Memorial University of Newfoundland
• MemorialCare Health System
• Merck
• Merge Healthcare
• Metabiomics
• MetaboGen
• Michael E. DeBakey Veterans Affairs Medical Center
• Mitchell Cancer Institute
• Microba
• Microbiome Diagnostic Partners
• Microbiome Health Research Institute
• Microbiome Insights
• Microbiome Research Centre
• MicroBiome Therapeutics
• Microbiome Therapeutics Innovation Group
• MicrobiomeDx
• Microbiotica
• Microinventa
• Microsoft
• Microviable Therapeutics
• Millennium Pharmaceuticals
• Miomics
• Miyarisan Pharmaceutical
• Modena University Hospital
• Molzym
• Monash University
• Montefiore Medical Center
• Moon Biotech
• Mount Sinai Hospital
• mybacs
• MyBiotics
• MyMicroZoo
• NAFLD Research Center, University of California San Diego School of Medicine
• Naked Biome
• Nantes University Hospital
• National Cancer Institute (NCI)
• The National Institute for Health and Care Excellence (NICE)
• National Institute of Allergy and Infectious Diseases (NIAID)
• The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• National Institute for Health and Medical Research (INSERM)
• National Institutes of Health (NIH)
• National Jewish Health
• National PKU Alliance
• Nationwide Children's Hospital
• Nestl Health Science
• New York University
• New Zealand Society of Gastroenterology
• NIZO
• Nordland Hospital Trust
• NorthShore University HealthSystem
• Norway Regional Health Authority
• Norwegian University of Science and Technology
• Novartis
• Novo Nordisk
• Novogene
• Novome Biotechnologies
• Nubiyota
• Open Patient data Explorative Network
• Odense University Hospital
• Ohio State University Wexner Medical Center
• Omega Biomics
• One Codex
• OpenBiome
• OptiBiotix
• Oragenics
• Oralta
• Orebro University
• Oregon State University
• Orexigen Therapeutics
• Osel
• OSI Pharmaceuticals
• Oslo University Hospital
• OxThera
• Pacific Northwest National Laboratory (PNNL)
• Paragon Bioservices (unit of Catalent Biologics)
• Parker Institute for Cancer Immunotherapy
• Vlaamse Parkinson Liga
• Parkinson's Institute and Clinical Center
• Peking Union Medical College Hospital
• Pendulum Therapeutics (formerly known as Whole Biome)
• Perrigo
• Persona Biome
• Pfizer
• Pharmacia & Upjohn
• Pharm-Olam
• Phase Genomics
• Phi Therapeutics
• Phylagen
• Pierre and Marie Curie University
• Pierre Fabre
• Pillar Healthcare
• Postbiotics Plus
• Postgraduate Institute of Medical Education and Research
• PrecisionBiotics
• Presutti Laboratories
• Prime Discoveries
• Priority Health
• Probiotical
• ProdermIQ
• ProDigest
• Prometheus Laboratories
• PSI Foundation
• Psoriasis Association
• Psychiatric Hospital of the University of Basel
• Public Health England
• Public Health Ontario
• Puerta de Hierro University Hospital
• Qiara
• Qingdao Institute of Bioenergy and Bioprocess Technology
• Quadram Institute
• Quay Pharma
• Queen Elizabeth II Health Sciences Centre
• Queen's University
• Quorum Innovations
• Quotient Sciences
• Rambam Healthcare Campus
• Rebiotix (part of Ferring Pharmaceuticals Group)
• Regence BlueShield
• Regeneron Pharmaceuticals
• Replete Biotics
• Research Foundation - Flanders
• Research Institute of St Joe's Hamilton
• Resilient Biotics
• Resphera Biosciences
• Rise Therapeutics
• Ritter Pharmaceuticals
• Roche
• RondinX (Acquired by BiomX)
• Roswell Park Comprehensive Cancer Center
• Ruprecht Karl University of Heidelberg
• Rush University
• Sabinsa
• Saint-Antoine Hospital
• Salix Pharmaceuticals
• Sanofi
• S-Biomedic
• Scaled Microbiomics
• SciBac
• Scioto Biosciences
• Seattle Children's Hospital
• Second Genome
• Seed Health
• Santa Maria della Misericordia Hospital
• Seres Therapeutics
• SFA Therapeutics
• Shanghai Children's Medical Center
• Shanghai General Hospital
• Shanghai Jiao Tong University School of Medicine
• Shanghai Zhongshan Hospital
• Sheba Medical Center
• Shoreline Biome
• Sicor
• Siffra Farmaceutici
• Sinai Health System
• Siolta Therapeutics
• Sjogren's Syndrome Foundation
• SkinBioTherapeutics
• Snipr Biome
• Solarea Bio
• Soroka Medical Center
• SRZ Properties
• St. Justine's Hospital
• Stanford Cancer Institute
• Stanford University School of Medicine
• Stony Brook University
• Sucampo Pharmaceuticals
• Sugarlogix
• Sun Genomics
• Symberix
• Symbiota
• Symbiotix Biotherapies
• Syneos Health
• Synergy Worldwide
• Synlogic
• Synthetic Biologics
• Synthetic Genomics
• Taiho Pharmaceutical
• Takeda Pharmaceutical
• TargEDys
• Tel Aviv Sourasky Medical Center
• Temple University
• Teva Pharmaceutical
• Texas Digestive Diseases Center
• Texas Children's Hospital
• The BioCollective
• The Chinese University of Hong Kong
• The Danish Rheumatism Association
• The Flanders Institute for Biotechnology
• The Jackson Laboratory
• The Miriam Hospital
• The Research Council of Norway
• The Second Affiliated Hospital of Nanjing Medical University
• The University of Texas Health Science Center
• The University of Texas MD Anderson Cancer Center
• The Weston A Price Foundation
• Thryve Digital
• Tongji Hospital
• Toronto Invasive Bacterial Diseases Network
• Tortuga Biosciences
• Trayer Biotherapeutics
• Triphase Pharmaceuticals
• TULA Skincare
• uBioDiscovery
• uBiome
• UCB Pharma
• Ume University
• Universitair Ziekenhuis Leuven
• University Health Network
• University Hospital Cologne
• University Hospital of Limoges
• University Hospital of North Norway
• University of Adelaide
• University of Alberta
• University of British Columbia
• University of Calgary
• University of California
• University of Chicago
• University of Chieti
• University of Florence
• University of Maryland
• University of Massachusetts
• University of Melbourne
• University of Miami
• University of Minnesota
• University of Modena and Reggio Emilia
• University of New South Wales
• University of North Carolina
• University of North Texas
• University of Oslo
• University of Pennsylvania
• University of Pittsburgh
• University of Portsmouth
• University of Southern Denmark
• University of Surrey
• University of Texas
• University of Toronto
• University of Tromso
• University of Vermont
• University of Wisconsin
• University of Zurich
• US Army Medical Research and Materiel Command
• US Department of Veterans Affairs
• VA Office of Research and Development
• Vaiomer
• Vancouver General Hospital
• Varinos
• Vast Biome
• Vedanta Biosciences
• Vertex Pharmaceuticals
• Viome
• Virginia Commonwealth University
• Visbiome
• ViThera Pharmaceuticals
• Vitrilife
• Vivus
• WACKER (formerly known as Synco Bio)
• Washington University School of Medicine
• Weill Cornell Medical College of Cornell University
• Wellmicro
• Western Sydney Local Health District
• Westmead Institute for Medical Research
• Winclove Probiotics
• Wolfson Medical Center
• Women's College Hospital
• Xbiome
• Xycrobe Therapeutics
• Yakult Honsha
• Yonsei University
• Zehna Therapeutics
• ZMD Group

For more information about this report visit https://www.researchandmarkets.com/r/bbz676

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.